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Genetic alterations of ARID1B have been recently recognized as one of the most
common mendelian causes of intellectual disability and are associated with both
syndromic and non-syndromic phenotypes. The ARID1B protein, a subunit of the
chromatin remodeling complex SWI/SNF-A, is involved in the regulation of
transcription and multiple downstream cellular processes. We report here the
clinical, genetic, andproteomicphenotypesof an individualwith auniqueapparent de
novo mutation of ARID1B due to an intragenic duplication. His neurodevelopmental
phenotype includes a severe speech/language disorder with full scale IQ scores 78–
98and scattered academic skill levels, expanding thephenotypic spectrumofARID1B
mutations. Haploinsufficiency of ARID1B was determined both by RNA sequencing
and quantitative RT-PCR. Fluorescence in situ hybridization analysis supported an
intragenic localizationof theARID1B copynumber gain. Principal component analysis
revealed marked differentiation of the subject’s lymphoblast proteome from that of
controls.Of 3426proteins quantified, 1014were significantly up- or down-regulated
compared to controls (q < 0.01). Pathway analysis revealed highly significant
enrichment for canonical pathways of EIF2 andEIF4 signaling, protein ubiquitination,
tRNA charging and chromosomal replication, among others. Network analyses
revealed down-regulation of: (1) intracellular components involved in organization of
membranes, organelles, and vesicles; (2) aspects of cell cycle control, signal
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transduction, and nuclear protein export; (3) ubiquitination and proteosomal
function; and (4) aspects of mRNA synthesis/splicing. Further studies are needed
to determine the detailedmolecular and cellular mechanisms bywhich constitutional
haploinsufficiency of ARID1B causes syndromic and non-syndromic developmental
disabilities.
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SWI/SNF, SWI/SNF-A
1 | INTRODUCTION
Intellectual disability is characterized by significant limitations in
cognitive functioning and adaptive behaviors (American Psychiatric
Association, 2013) and affects 1–3% of the general population.
Mutations of ARID1B (AT-rich interactive domain 1B) are an
epidemiologically significant subset of mendelian causes of neuro-
developmental disability and are associated with non-syndromic
intellectual disability as well as syndromic forms of intellectual
disability such as Coffin–Siris syndrome (Hoyer et al., 2012; Santen
& Clayton-Smith, 2014; Sim, White, & Lockhart, 2015). The
product of ARID1B is a ubiquitous nuclear-localized protein that
is a subunit of SWI/SNF-A, a chromatin remodeling complex that
contains over 25 core subunits and that is involved in the
regulation of many biological processes, including regulation of
transcription (Euskirchen, Auerbach, & Snyder, 2012). ARID1B
mutations associated with intellectual disability include whole gene
deletions, intragenic deletions, splice site, nonsense, and frameshift
mutations, all of which point to haploinsufficiency as the
mechanism causing the phenotype, as well as rare and less well-
studied duplications (reviewed in Santen & Clayton-Smith, 2014;
Sim et al., 2015). Here, we report the clinical, genetic, and
proteomic findings of an individual having a unique loss-of-
function mutation of ARID1B due to an intragenic duplication.
2 | CLINICAL REPORT
This study was approved by the Institutional Review Board of the
Cleveland Clinic. The subject is a 14-year-old male born at 39weeks of
gestation to a healthy primagravida 38-year-old mother and unrelated
49-year-old father with non-contributory family histories. There were
no medical concerns during infancy. Early developmental milestones
were met until 1-year of age but no use of sentences occurred until
about 2.5–3 years old.
Physical examinations during early childhood noted language
delays, borderlinemacrocephaly, strabismus, dysarthria, mild hypotonia
and mild gross and fine motor incoordination. Diminished physical
endurance was also apparent in early childhood and has persisted. He
had prolonged recovery times from illnesses, including several
developmental regressions that lasted 2 or more months between
ages 7–9 years, as well as two episodes of difficulty recovering from
general anesthesia at 3 and6yearsold.Ophthalmologic exam revealeda
right optic nerve pit. Growth parameters at 6.5 years included head
circumference 54.8 cm (98%), weight 22.1 kg (52%), and height
116.9 cm (38%). Physical exam at 12.4 years showed a non-dysmorphic
male with weight 36.6 kg (18%) and height 140.3 cm (7%); neurological
exam showed slowed processing to questions or directions, abnormal
gait with bilateral intoeing, mild imbalance, mild dysmetria, slow rapid
alternating movements, and clumsy fine motor function.
The earliest neuropsychological assessment, at 3.5 years, used the
Stanford Binet 5 tool and showed full-scale IQ 98, verbal IQ 122, and
non-verbal IQ74.At5 years, using theWPPSI-III, hewasnoted tohavea
full-scale IQ 83, verbal IQ 78, and non-verbal IQ 96, a poor fund of
general knowledge and difficulty formulating and expressing verbal
concepts.At8 years, using theWISC-4, therewasa full-scale IQ78,with
verbal comprehension 85, perceptual reasoning 102, working memory
86, and processing speed 50. His strongest skills related to nonverbal
visual-spatial reasoning. There was slow processing of information,
deficiency of working memory, and poor visual/graphomotor skills. He
was diagnosed with a severe language disorder. Auditory evaluation at
10 years showed an auditory processing disorder with severe difficulty
in figure-ground discrimination, integration of words and sentences,
temporal integration and phonological processing, and low average
auditory comprehension, and average auditory short-term memory. At
12.5 years, using the Wide Range Achievement Test-4, he scored 101,
104, 91, and 67 inword reading, sentence comprehension, spelling, and
math computation, respectively.
Cranial MRIs at 6 months and 7 years of age showed a mildly
dysmorphic corpus callosum. A 48 hr EEG at 5 years was unremarkable.
Routine blood tests and urinalysis were normal. Normal metabolic testing
included thyroid function tests, plasma amino acids, blood ammonia, and
urinary organic acids, acylglycines, guanidinoacetate and creatine.
Newborn screening, including for galactosemia, was negative. A fasting
global plasmametabolomic analysis was unremarkable. The blood lactate
and plasma butyrylcarnitine levels were intermittently increased. The
fibroblast lactate:pyruvate ratio was normal, as were activities of
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fibroblast electron transport chain complexes II, III, and IV and pyruvate
dehydrogenase. A fibroblast loading study for defects of mitochondrial
fatty acidbeta-oxidationwasnegative.A lymphocyte cytogenetic analysis
showed a normal 46,XY karyotype at the 550 band resolution. Whole
exome sequencing did not reveal pathogenic variants that were likely or
definitely related to the clinical phenotype. A separate sequencing of the
mitochondrial genome was unremarkable.
Array CGH showed a copy number gain within chromosome band
6q25.3 of approximately 0.361Mb in size, arr [GRCh37] 6q25.3
(157133792–157495187)x3 dn (Figure 1b). The duplication, which
was not observed in either parent, involves a segment containing
exons 2–10 (ENST00000346085) of ARID1B. Array analysis also
showed heterozygosity for an approximately 0.003Mb maternally
inherited copy number loss, arr [GRCh37] 9p13.3(34647598–
34650608)x1 mat, including part of GALT. There was no clinical or
biochemical evidence for galactosemia, nor was a mutation of the
other GALT allele detected.
3 | MATERIALS AND METHODS
3.1 | Molecular cytogenomic analysis
Array CGH was performed on a 400 K oligonucleotide microarray
(version 10.2) designed by theMedical Genetics Laboratories at Baylor
College ofMedicine and manufactured by Agilent Technologies (Santa
Clara, CA). It includes exonic coverage of over 4,000 candidate and
disease genes at an average resolution of 30 kb with 60,000 SNP
probes and 670 probes for the mitochondrial genome. Data was
extracted using Agilent’s Feature Extraction software (version 9.5.3.1)
and was analyzed using a web-based software platform (Cheung et al.,
2005; Lu et al., 2007).
3.2 | Transcriptome analysis
Gene expression was measured by RNAseq and quantitative
RT-PCR. Total RNA was extracted from a patient-derived
EBV-transformed lymphoblastoid cell line (LCL) and control EBV-
transformed LCLs using TRIzol® (Invitrogen, Carlsbad, CA)
followed by RNeasy Mini Kit (Qiagen, Hilden, Germany) column
purification. cDNA was synthetized from 1 μg of extracted RNA
using SuperScript® II Reverse Transcriptase (ThermoFisher Scien-
tific, Waltham, MA) with oligo(dT), random hexamers, and RNase
inhibitor. The RNAseq library was prepared using the Illumina
TruSeq kit and manufacturer’s instructions (Illumina, San Diego
CA). Libraries were multiplexed, pooled and sequenced on multiple
lanes of an Illumina HiSeq2500, generating an average of 30 million
paired-end reads of 76 bp. Quality assessment of sequence
reads was performed using fastQC (v. 0.10.1) (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). Sequence reads
were then aligned to human reference genome Ensembl GRCh37
(v. 71) using GSNAP (v. 12-19-2014) (Wu & Nacu, 2010) at its
default parameter setting. Quality checking of alignments was
assessed by a custom script utilizing Picard Tools (http://
broadinstitute.github.io/picard/), RNASeQC (DeLuca et al., 2012),
RSeQC (Wang, Wang, & Li, 2012), and SamTools (Li et al., 2009).
Novel transcript analysis was performed using Cufflinks, and
FIGURE 1 Molecular and genetic characterization of the ARID1B microduplication. (a) Representation of the ARID1B transcripts expressed
in the patient with exon numbering based on an Ensembl transcript ENST00000346085. (b) Array CGH shows the duplicated region
comprising exons 2 to 10 between the vertical lines. (Green dots represent probes with log ratio above 0.2 and red dots those with log ratio
below −0.2. Duplication or deletion is considered when probes are ≥0.4 or ≤−0.6, respectively.) (c) Sashimi plots generated from the RNAseq
datasets depict the splice junctions that have a minimum of 3 reads supporting each junction. No novel junctions are observed in the patient.
(d) FISH analysis (performed with a BAC clone, RP11-680A17, labeled in red and a control probe, RP11-719E16, labeled in green) confirms
the duplication in interphase and metaphase cells, showing the duplication on chromosome 6 (as indicated by the white arrow) and not
inserted into another chromosome. (e) (left to right) Decreased expression levels of ARID1B measured by qRT-PCR (using primers on exon 9
and on the junction of exons 10 and 11), in comparison to 7 age- and gender-matched controls (p-val 0.02), and by RNAseq in comparison to
5 age-matched controls. Error bars represent standard deviation. Transcript abundance analysis in the patient shows the 3 ARID1B expressed
transcripts, measured from the RNAseq dataset using Cufflinks.
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visualized on Integrative Genomics Viewer (Robinson et al., 2011;
Thorvaldsdóttir, Robinson, & Mesirov, 2013). Counts per Million,
generated from gene level counts which were tabulated using
BedTools’s multibamcov algorithm (v. 2.17.0) (Quinlan & Hall,
2010) on unique alignments for each library at all Ensembl genes
(GRCh37 v.71), were calculated to compare expression levels with
control samples from five healthy individuals.
3.3 | Quantitative RT-PCR
QuantitativeRT-PCRwasperformed forARID1Busing customdesigned
primers and ACTB, GAPDH and POLR2A were used as endogenous
controls. Primers were as described: ARID1B (forward −
tgcgtcccctcatctctcca, reverse − aggcatctgactacctggga), ACTB (forward
− tgaagtgtgacgtggacatc, reverse − ggaggagcaatgatcttgat), GAPDH
(forward − ggacctgacctgccgtctag, reverse − gtagcccaggatgcccttga),
POLR2A (forward − gcaccacgtccaatgacat, reverse− gtgcggctgcttccataa).
Primers (0.75 μM final), cDNA (1:100 final) and nuclease-free water
were added to the LightCycler® 480 SYBR Green I Master Mix (Roche)
for a final 10 μL reaction volume. A LightCycler® 480 (Roche) was used
for data acquisition. Values for the subject and seven age- and gender-
matched controls were obtained in at least three technical replicates.
Results of technical replicates for ARID1B were normalized and
compared against the average of the three endogenous gene controls
using theΔΔCtmethod. Results areexpressed as fold-change relative to
the averaged control individuals. A two-tailed T-test was used to assess
statistical significance.
3.4 | Fluorescence in situ hybridization
Peripheral blood from the proband was collected in a sodium heparin
vacutainer tube, cultured for 72 hr with the mitogen phytohemag-
glutinin, and harvested by standard cytogenetic methods. Slides
containing both interphase and metaphase cells were hybridized
according to standard protocol with fluorescently labeled BAC
clones, RP11-680A17 and RP11-719E16, localized to 6q25.3 and
6q13, respectively. The BAC clones had been grown in broth
medium with 20 μg/ml of chloramphenicol followed by DNA
extraction using a Plasmid Miniprep kit (Qiagen). The target clone,
RP11-680A17, was labeled directly with Spectrum GreenTM dUTP
by nick translation with the Abbott Molecular kit. After hybridization
and in accordance with the laboratory’s standard confirmation
protocol for duplications less than 1Mb, 50 interphase cells were
manually scored using a fluorescent microscope to confirm the
presence of the duplication and a metaphase cell was examined to
confirm the localization of the duplicated segment.
3.5 | Proteome analysis
LCLs from the subject, obtained at 13 years of age, and 5male controls
ages 31–40 years were used. A total of 15 µg of protein from each
sample was digested with LysC for 1 hr and trypsin overnight at 37°C.
Reverse phase LC-MS/MS was performed as described (Tomechko
et al., 2015), except that 600 ng of peptide digests was loaded on the
HPLC column and the gradient of solvent B ranged from 2% to 40%
over 210min.
Raw LC-MS/MS data files for each sample were processed using
Rosetta Elucidator (Rosetta Biosoftware, Seattle, WA) (Version 3.3.01
SP4 25). Automated differential quantification of peptides was
performed as previously described (Azzam et al., 2016; Neubert
et al., 2008; Schlatzer, Sugalski, Dazard, Chance, & Anthony, 2012).
Briefly, LC-MS/MS raw datawere imported, and for eachMS spectrum
profile of each LC-MS/MS run, chromatographic peaks, and mono-
isotopic masses were extracted and aligned. Chromatographic peaks
were first aligned by retention time and monoisotopic mass. Peaklists
with the monoisotopic mass and corresponding MS/MS data were
then generated for each sample and searched using Mascot. Resultant
peptide identifications were imported into Elucidator and monoiso-
topic masses annotated with peptide identifications. The false
discovery rate for protein identifications was calculated to be
0.02%. The MS/MS peak lists were searched by Mascot (version
2.4.1) (Matrix Science, London, UK) using the humanUniProt database.
Search settings were as follows: trypsin enzyme specificity; mass
accuracywindow for precursor ion, 25 ppm;mass accuracywindow for
fragment ions, 0.8 Da; variable modifications including carbamido-
methlylation of cysteines, one missed cleavage and oxidation of
methionine.
3.6 | Statistical methods and bioinformatic analyses
Raw MS data were obtained for each region in a csv file; this file
contained intensity values, with rows corresponding to peptides and
columns corresponding to the sample. Missing values were imputed
using a weighted k-nearest neighbors algorithm (Troyanskaya et al.,
2001). Next, data were log2-transformed to achieve normality. Data
were visualized with principal component analysis and complete
linkage hierarchical clustering. These preprocessing steps were
performed using InfernoRDN (formerly DanTE) (Polpitiya et al.,
2008). Data were imported into the R statistical programming
environment for subsequent analyses.
Because there was one case and multiple controls, we treated
individual peptides as observations of a given protein. Therefore,
proteins with only one quantified peptide were excluded from our
analysis. To compare protein abundance between the case and
controls, we constructed a linear mixed effects model that adjusted
for subject to account for the non-independence of peptides derived
from the same sample. Proteins with q < 0.01 were imported into
DAVID version 6.8 (https://david.ncifcrf.gov/tools.jsp) for ontology
analysis. EASE score threshold was set at a value of 1.0 and minimum
count for an annotation term was set to 3. The entire set of proteins
with more than one peptide (n = 2,351) was used as background for
enrichment analysis. Network and pathway analyses were per-
formed in Ingenuity Pathway Analysis (IPA®, www.qiagen.com/
ingenuity); proteins with q-value < 0.01 were used for this purpose.
Network connections were curated based on data from all species
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and all cell lines and tissues. Enrichment scores and p-values for
canonical pathway and network analysis were determined by a
one-tailed Fisher’s exact test.
4 | RESULTS
Measurement of ARID1B expression by quantitative RT-PCR showed a
significant decrease of mRNA levels in the patient in comparison to
control subjects (p-value 0.02) and a similar result was observed using
RNAseq (Figure 1e). Allele-specific expression could not be assessed
since the subject was not heterozygous for SNPs located in coding
exons or in the untranslated regions. The most abundant mRNA
transcript observed in the RNAseq dataset was ENST00000414678,
consistent with the GTEx database for EBV-transformed lympho-
blasts; ENST00000350026 and ENST00000346085 were also
detected in the patient sample (Figure 1e). IGV Sashimi plots did not
reveal novel junctions or transcripts for this gene (Figure 1c), providing
no evidence that duplication of this exonic region resulted in
alterations in splicing.
Follow-up fluorescence in situ hybridization analyses showed the
presence of duplicated ARID1B genome in interphase cells (Figure 1d).
The latter, in turn,was localized to chromosome6q25.3 on analysis of a
metaphase cell, the site of theARID1B gene (Figure 1d), confirming that
the microduplication occurred within the same chromosome and
excluding the hypothesis of complex rearrangements.
Proteomic analyses of the LCLs resulted in the quantification of
15,792 peptides, corresponding to 3,426 proteins. There were 1,014
proteins that were differentially expressed between the case and
controls (q < 0.01). The differentially expressed proteins and related
data are noted in Supplementary Table S1. Principal component
analysis and hierarchical clustering analysis revealed marked separa-
tion of the subject’s proteome from that of controls (Supplementary
Figure S1).
Gene ontology analysis in DAVID revealed enrichment of several
annotation clusters with terms relating to ATP binding, mitochondrion,
and flavin adeninedinucleotide (SupplementaryTableS2). Bioinformatic
analysis with IPA® revealed enrichment for canonical pathways of EIF2
signaling (p-value 6.31 E-17), protein ubiquitination (p-value 1.58 E-16),
regulation of eIF4 and p70S6K signaling (p-value 1.00 E-14), tRNA
charging (p-value 5.01 E-13), and cell cycle control of chromosomal
replication (p-value 6.31 E-11) (Supplementary Table S3). Down-
regulation of: (1) intracellular components involved in intracellular
organization of membranes, organelles, and vesicles; (2) aspects of cell
cycle control, signal transduction, and nuclear protein export; (3)
ubiquitination and proteosomal function; and (4) aspects of mRNA
synthesis/splicing are noted in IPA® network analyses (Supplementary
Figures S2a–d).
5 | DISCUSSION
The subject has a unique ARID1B mutation, a copy number gain
involving part of that gene that was initially determined by a
chromosomal microarray analysis and which was thought likely to
cause a pathologic reduction of ARID1B gene expression. Subse-
quent gene expression data, by both qRT-PCR and RNAseq,
indicated haploinsufficiency of ARID1B and was consistent with
localization of the duplication within the ARID1B gene, disrupting
expression of the affected allele. Confirmation that there is a large
intragenic ARID1B duplication was established by a fluorescence in
situ hybridization analysis. Haploinsufficiency for ARID1B is likely
to be the cause of developmental delay in this individual as no
additional genetic or metabolic defects were identified. While the
measurement of RNA in LCLs does not necessarily reflect the
effect of the genetic lesion in the brain, the association of
heterozygous inactivating mutations in ARID1B with neurodeve-
lopmental phenotypes in other subjects suggests that reduced
gene expression also occurs in the central nervous system. As
ARID1B is expressed at different levels in the brain, namely
higher in the cerebellum than in many peripheral tissues and
other measured areas of the brain (http://www.gtexportal.org/),
the consequences of its reduced expression may be even more
pronounced there, possibly accounting for aspects of subject’s
phenotype.
There are two reports of smaller microduplications of
ARID1B. The clinical and genetic phenotypes of these two
individuals and our case are summarized in Supplementary
Table S4. Our case has several unique aspects to his phenotype.
Few individuals with ARIB1B haploinsufficiency are reported with
low-normal intellectual function (Santen & Clayton-Smith, 2014).
Our patient, while having a significant speech/language disorder
and cognitive disability, has had several IQ determinations within
the normal range but there was considerable (and reproducible)
variability in selected skills. In addition, his clinical course has
been characterized by easy fatigability and episodes of develop-
mental regression, prompting evaluation for a possible metabolic
underpinning of these clinical concerns. Apart from intermittent
elevated blood lactate levels, extensive metabolic testing was
unrevealing. To our knowledge, other cases of individuals with
ARID1B haploinsufficiency do not have histories of episodic
regression, although the episodic memory dysfunction in one
case may be relevant (Yu et al., 2015).
Our results support the view that ARID1B is a dosage
sensitive gene whose expression can be affected by deletions
or duplications. Indeed, the evolutionary constraint on this gene
shows that it is highly intolerant to loss-of-function mutations
according to its ExAC pLI score of 1.00 (http://exac.
broadinstitute.org/). As we did not identify novel transcripts,
the duplicated allele either was not transcribed or was tran-
scribed but its RNA was degraded by surveillance mechanisms.
Other chromatin regulators have also been noted to be dosage
sensitive causes of neurodevelopmental phenotypes, including
MBD5, EHMT1, CHD8, and SATB2 (Talkowski et al., 2012).
The lymphoblast proteomic data are striking: statistically
highly significant dysregulation of pathways related to initiation
of translation were noted, in addition to dysregulation of pathways
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and networks relating to protein ubiquitination, mTOR signaling,
apoptosis, major metabolic pathways (e.g., TCA cycle, mitochon-
drial oxidative phosphorylation), cell cycle control, mRNA
synthesis/processing, and intracellular vesicular transport. A
number of the differentially expressed pathways and networks
relate to described roles of ARID1B and the SWI/SNF-A chromatin
remodeling complex in different tissues such as cell cycle
regulation, ubiquitination, mRNA synthesis/processing, apoptosis,
and intracellular signaling pathways (Li, Trojer, Matsumura,
Treisman, & Tanese, 2010; Nagl, Wang, Patsialou, Van Scoy, &
Moran, 2007; Raab, Resnick, & Magnuson, 2015; Sim et al., 2015;
Xi, He, Zhang, Le, & Massagué, 2008); involvement of other
pathways, including many metabolic pathways and intracellular
vesicular trafficking, is newly described. Our data do not
specifically implicate dysregulation of Wnt/β-catenin signaling
as was noted in another recent study (Vasileiou et al., 2015).
Yet, although our proteomic analysis indicates widespread
and marked differential expression of proteins in the ARID1B
haploinsufficient lymphoblasts, there are three important potential
limitations of these findings: first, one cannot generalize these
results until proteomic analysis of additional cases of ARID1B
haploinsufficiency are carried out; second, the proteomic findings,
while predictive of marked dysregulation of multiple pathways
and networks, do not reveal which dysregulated pathways are of
greatest pathophysiological significance; and, third, the relevance
of lymphoblast findings to brain biology (and that of other tissues)
is uncertain.
The roles of ARID1B in brain development are starting to be
understood. Recent studies reveal that it may be critical in cell
proliferation and differentiation and is important in dendritic
arborization, and synapse formation (Harmacek et al., 2014; Nagl
et al., 2007; Tuoc et al., 2013; Yan et al., 2008). Consequently,
ARID1B deficiency may result in neurodevelopmental defects via
abnormal brain wiring induced by the defective differentiation of
neurons (Ka, Chopra, Dravid, & Kim, 2016). This report provides
additional perspectives regarding ARID1B haploinsufficiency and
its associated developmental disabilities. Further studies are
needed to understand the precise mechanisms whereby altered
chromatin remodeling leads to changed brain development and
cognitive function.
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